InsiderSignal.AI

InsiderSignal.ai

BCAX - Bicara Therapeutics Inc.

Insider Sale by Mazumdar Claire (CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

Yesterday, Mazumdar Claire, serving as CEO at Bicara Therapeutics Inc. (BCAX), sold 15,000 shares at $23.61 per share, for a total transaction value of $354,146.00. Following this transaction, Mazumdar Claire now holds 362,152 shares of BCAX.

This sale represents a 4.00% decrease in Mazumdar Claire's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Monday, April 20, 2026 and publicly disclosed via SEC Form 4 filing on Monday, April 20, 2026, meaning the disclosure happened on the same day as the trade.

Bicara Therapeutics Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Mazumdar Claire

CEO

Claire Mazumdar, Ph.D., M.B.A., is the founding Chief Executive Officer and Class III director of Bicara Therapeutics Inc. (NASDAQ: BCAX), a clinical-stage oncology company focused on developing therapies for difficult-to-treat cancers, such as head and neck squamous cell carcinoma (HNSCC).[[1]](https://ng.investing.com/news/company-news/-relay-therapeutics-appoints-bicara-ceo-to-board-ahead-of-breast-cancer-trial-93CH-1963337)[[2]](https://fintool.com/app/research/companies/BCAX/people/claire-mazumdar)[[3]](https://relaytx.com/our-team/claire-mazumdar/) Under her leadership since January 2020, Bicara advanced its lead candidate ficerafusp alfa into the pivotal Phase 2/3 FORTIFI-HN01 trial in February 2025, secured FDA Breakthrough Therapy Designation for 1L HPV-negative HNSCC in November 2025, completed a $362 million IPO in September 2024, and reported $407.6 million in cash equivalents as of September 30, 2025, providing a runway into H1 2029.[[2]](https://fintool.com/app/research/companies/BCAX/people/claire-mazumdar)[[4]](https://economictimes.com/magazines/panache/meet-kiran-mazumdar-shaws-niece-claire-an-mit-grad-making-indian-innovation-shine-with-1-billion-market-debut/articleshow/113737214.cms)[[5]](https://timmermanreport.com/2025/07/a-two-pronged-attack-on-cancer-claire-mazumdar-on-the-long-run/) Prior to Bicara, Mazumdar served as Head of Business Development and Corporate Strategy at Rheos Medicines (2017–2019), where she helped secure a multi-target discovery partnership with Roche Pharmaceuticals, and as an Investment Professional at Third Rock Ventures, focusing on company formation and business development.[[1]](https://ng.investing.com/news/company-news/-relay-therapeutics-appoints-bicara-ceo-to-board-ahead-of-breast-cancer-trial-93CH-1963337)[[2]](https://fintool.com/app/research/companies/BCAX/people/claire-mazumdar)[[3]](https://relaytx.com/our-team/claire-mazumdar/) She holds a B.S. in biological engineering from the Massachusetts Institute of Technology, a Ph.D. in cancer biology from Stanford School of Medicine, and an M.B.A. from Stanford Graduate School of Business.[[1]](https://ng.investing.com/news/company-news/-relay-therapeutics-appoints-bicara-ceo-to-board-ahead-of-breast-cancer-trial-93CH-1963337)[[2]](https://fintool.com/app/research/companies/BCAX/people/claire-mazumdar)[[3]](https://relaytx.com/our-team/claire-mazumdar/) Notably, she is the niece of Biocon founder Kiran Mazumdar-Shaw, with Biocon entities holding an 11% stake post-IPO, and she serves on the board of non-profit Noora Health.[[2]](https://fintool.com/app/research/companies/BCAX/people/claire-mazumdar)[[4]](https://economictimes.com/magazines/panache/meet-kiran-mazumdar-shaws-niece-claire-an-mit-grad-making-indian-innovation-shine-with-1-billion-market-debut/articleshow/113737214.cms)

View full insider profile →

Trade Price

$23.61

Quantity

15,000

Total Value

$354,146.00

Shares Owned

362,152

Trade Date

Monday, April 20, 2026

1 days ago

SEC Filing Date

Monday, April 20, 2026

HEALTHCAREBIOTECHNOLOGY

About Bicara Therapeutics Inc.

Company Overview

No company information available
View news mentioning BCAX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5810043

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime